TE 方案新辅助化疗前后60 岁以上乳腺癌合并 糖尿病患者肾功能指标的变化分析

目的 探讨分析60 岁以上乳腺癌合并糖尿病患者在TE 方案新辅助化疗前后血肌酐（Scr）、尿素 氮（BUN）、血清胱抑素C（CysC）的变化规律及特征。方法 选取哈励逊国际和平医院86 例60 岁以上乳 腺癌合并糖尿病患者，分析TE 方案新辅助化疗前后Scr、BUN、CysC 检测结果情况。结果 60 岁以上乳腺 癌合并糖尿病患者新辅助化疗后Scr、BUN、CysC 检测结果均呈现增高趋势，Scr 检测结果在新辅助化疗前 后差异无统计学意义（P >0.05），BUN 检测结果在新辅助化疗前后差异无统计学意义（P >0.05），CysC 检测 结果在新辅助化疗前后差异有统计学意义（P <0.05）。结论 60 岁以上乳腺癌合并糖尿病患者新辅助化疗后 CysC 升高，表明TE 方案新辅助化疗对有糖尿病既往病史的乳腺癌患者的肾功能造成一定损害，监测乳腺癌 患者新辅助化疗过程中肾功能的变化有重要临床指导意义。

Renal function index changes before and after TE scheme of neoadjuvant chemotherapy in elderly breast cancer patients with diabetes mellitus

Objective To investigate the change rules and characteristics of Scr, BUN and CysC in over 60- year breast cancer patients with diabetes mellitus before and after TE scheme neoadjuvant chemotherapy. Methods Eighty-six breast cancer patients over 60 years complicated with diabetes mellitus were selected from Harrison International Peace Hospital. Scr, BUN and CysC before and after TE scheme neoadjuvant chemotherapy were detected and analyzed. Results Scr, BUN and CysC detection results of the breast cancer patients with diabetes mellitus showed increasing trends after neoadjuvant chemotherapy. Scr and BUN detection results were not statistically different before and after neoadjuvant chemotherapy ( P > 0.05), CysC detection results were significantly different before and after neoadjuvant chemotherapy (P < 0.05). Conclusions In over 60-year breast cancer patients with diabetes mellitus, CysC significantly increases after neoadjuvant chemotherapy, showing that TE scheme of neoadjuvant chemotherapy could induce certain renal damage to breast cancer patients with diabetes. Monitoring kidney function changes in the patients with breast cancer during the process of neoadjuvant chemotherapy has important clinical significance. Scr and BUN do not have significant changes before and after neoadjuvant chemotherapy.